A targeted Exos-based quadruple combination therapy significantly reduced tumor burden in vivo, suggesting a promising strategy for addressing tumor progression and TMZ resistance in NF1-mutated GBM [27,94]. This evidence concerns the gene NF1 and glioblastoma.